Cognition Therapeutics (NASDAQ:CGTX) Stock Rating Upgraded by Brookline Capital Management

Cognition Therapeutics (NASDAQ:CGTX) was upgraded by equities research analysts at Brookline Capital Management to a “strong-buy” rating in a research note issued to investors on Tuesday,Zacks.com reports.

Other research analysts also recently issued reports about the company. Wall Street Zen raised Cognition Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, November 8th. B. Riley restated a “buy” rating and issued a $3.00 price objective (up previously from $2.00) on shares of Cognition Therapeutics in a research note on Friday, November 21st. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Cognition Therapeutics in a research report on Monday, December 29th. Finally, HC Wainwright reissued a “buy” rating and issued a $3.00 price target on shares of Cognition Therapeutics in a report on Thursday, December 4th. One research analyst has rated the stock with a Strong Buy rating, three have given a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $3.33.

Cognition Therapeutics Stock Performance

Shares of NASDAQ:CGTX opened at $1.03 on Tuesday. The company has a market cap of $90.92 million, a P/E ratio of -2.15 and a beta of 1.25. The stock’s 50-day moving average is $1.47 and its 200-day moving average is $1.56. Cognition Therapeutics has a 52-week low of $0.22 and a 52-week high of $3.83.

Cognition Therapeutics (NASDAQ:CGTX) last posted its quarterly earnings data on Thursday, November 6th. The company reported ($0.06) earnings per share for the quarter, topping the consensus estimate of ($0.07) by $0.01. As a group, equities analysts predict that Cognition Therapeutics will post -0.8 EPS for the current year.

Hedge Funds Weigh In On Cognition Therapeutics

A number of hedge funds have recently made changes to their positions in CGTX. Jones Financial Companies Lllp bought a new position in shares of Cognition Therapeutics during the 3rd quarter worth about $25,000. Gamco Investors INC. ET AL acquired a new position in Cognition Therapeutics in the third quarter worth about $27,000. Private Management Group Inc. bought a new position in Cognition Therapeutics during the third quarter worth about $32,000. CWA Asset Management Group LLC bought a new position in Cognition Therapeutics during the third quarter worth about $34,000. Finally, Raymond James Financial Inc. boosted its holdings in Cognition Therapeutics by 34.7% during the third quarter. Raymond James Financial Inc. now owns 29,641 shares of the company’s stock valued at $40,000 after purchasing an additional 7,641 shares in the last quarter. Institutional investors and hedge funds own 43.35% of the company’s stock.

Cognition Therapeutics Company Profile

Cognition Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on developing disease-modifying therapies for neurodegenerative disorders, with an emphasis on Alzheimer’s disease. The company’s lead investigational candidate, CT1812, is an oral small molecule that antagonizes the sigma-2 receptor complex to protect synapses from amyloid-beta oligomer toxicity. By targeting a novel mechanism of action, Cognition Therapeutics aims to slow or reverse cognitive decline in patients living with Alzheimer’s disease.

CT1812 has successfully completed Phase 1 safety studies and preliminary Phase 2a trials, and is currently being evaluated in multiple Phase 2 clinical studies across North America and Europe in patients with mild-to-moderate Alzheimer’s disease.